What are the recommended treatment and management strategies for multi‑system atrophy (MSA)?

Treatment and Management of Multiple System Atrophy

Management of MSA is entirely symptomatic with a multimodal approach targeting motor symptoms with levodopa (especially in MSA-P), autonomic dysfunction with stepwise pharmacological and lifestyle interventions, and mandatory integration of physical therapy and multidisciplinary rehabilitation, as no disease-modifying therapies currently exist 1, 2.

Motor Symptom Management

Parkinsonian Features (MSA-P)

• Start with levodopa as first-line therapy for parkinsonian symptoms, though expect only partial and transient responses 1
• Levodopa works better in MSA-P subtype compared to MSA-C, but responses are typically limited and short-lived
• Dopaminergic agonists, MAO-B inhibitors, and amantadine provide minimal or short-lived benefit and should be considered secondary options 1
• Device-aided therapies (deep brain stimulation, spinal cord stimulation) are contraindicated in MSA 3

Critical caveat: Dopaminergic medications may worsen autonomic symptoms, particularly orthostatic hypotension, requiring careful balancing of motor benefit against autonomic side effects 2.

Cerebellar Ataxia (MSA-C)

• No effective pharmacological treatments exist for cerebellar symptoms
• Physical therapy and occupational therapy are the primary interventions for ataxia management 1

Emerging Motor Interventions

For specific motor complications like camptocormia (abnormal forward trunk flexion):

• Botulinum toxin injections to abdominal muscles showed the most substantial improvements in walking velocity, step length, and posture in recent case reports 3
• Repetitive trans-spinal magnetic stimulation (rTMS) showed modest improvements in functional mobility but limited postural effects 3
• Subcutaneous apomorphine improved gait parameters but was limited by nausea and hypotension 3

Non-Motor and Autonomic Symptom Management

Neurogenic Orthostatic Hypotension

Use a stepwise approach:

1. Lifestyle measures first: increased fluid intake (2-2.5L daily), increased salt intake (6-10g daily), compression stockings, head-up tilt during sleep, small frequent meals
2. Pharmacological agents: midodrine (alpha-1 agonist) or droxidopa as first-line medications
3. Fludrocortisone for volume expansion if initial agents insufficient

Urinary Dysfunction

• Anticholinergics (oxybutynin, tolterodine) for urinary urgency and frequency
• Intermittent catheterization for urinary retention
• Progression often leads to incontinence requiring comprehensive urological management 1

Gastrointestinal Dysmotility

• Constipation: polyethylene glycol, increased fiber, adequate hydration
• Dysphagia: speech therapy evaluation, dietary modifications, consider PEG tube in advanced disease

Sleep Disorders

• REM sleep behavior disorder: melatonin (3-12mg) or clonazepam (0.5-2mg) at bedtime
• Stridor: CPAP or BiPAP for nocturnal stridor; tracheostomy may be necessary in severe cases 1

Sexual Dysfunction

• Erectile dysfunction: sildenafil or other PDE-5 inhibitors (monitor for hypotension interaction)

Rehabilitation and Multidisciplinary Care

Physical therapy, occupational therapy, and multidisciplinary rehabilitation are integral and non-negotiable components of MSA management 1. These interventions:

• Maintain mobility and function longer than pharmacological interventions alone
• Address fall risk, which is a major cause of morbidity
• Provide adaptive strategies as disease progresses

Disease-Modifying Therapies

Currently, no disease-modifying therapies exist that significantly slow MSA progression 4. However, ongoing clinical trials focus on:

• α-synuclein-targeted therapies (antibodies, aggregation inhibitors)
• Neuroprotective agents
• Neuromodulation strategies 1, 5

Treatment Prioritization Algorithm

Base treatment decisions on the patient's most disabling symptoms 2:

1. If orthostatic hypotension with syncope dominates: Prioritize autonomic management even if it means limiting dopaminergic therapy
2. If parkinsonism is most disabling and MSA-P subtype: Trial levodopa up to 1000-1500mg daily, but monitor for autonomic worsening
3. If cerebellar ataxia predominates: Focus on intensive physical therapy and fall prevention
4. If multiple symptoms equally problematic: Coordinate care through multidisciplinary team involving neurology, autonomic specialists, physical/occupational therapy, urology, and primary care 2

Critical Pitfalls to Avoid

• Do not pursue aggressive dopaminergic therapy expecting Parkinson's disease-level responses; this leads to side effects without proportional benefit
• Do not overlook autonomic symptoms when treating motor symptoms; autonomic failure often determines quality of life more than motor impairment 5
• Do not delay physical therapy until motor symptoms are severe; early intervention maintains function longer
• Do not consider surgical interventions (DBS, spinal cord stimulation) as these are contraindicated and potentially harmful 3

The mean disease duration is approximately 6 years from diagnosis 6, with median survival of 8-10 years from symptom onset 7, making aggressive symptomatic management and quality of life optimization paramount throughout the disease course.